Navigation Links
Kaiser Permanente study shows link between caffeine and miscarriage
Date:1/20/2008

hemicals in coffee because caffeine intake from non-coffee sources such as caffeinated soda, tea and hot chocolate showed a similar increased risk of miscarriage.

The main message for pregnant women from these findings is that they probably should consider stopping caffeine consumption during pregnancy because this research provides clearer and stronger evidence that high doses of caffeine intake during pregnancy can increase the risk of miscarriage, said Li.

The reasons that caffeine can harm a fetus have been suspected for some time. Caffeine crosses through the placenta to the fetus, but can be difficult for the fetus to metabolize because of the under-developed metabolic system. Caffeine also may influence cell development and decrease placental blood flow, which may lead to an adverse effect on fetal development.

Women in the study were asked about their intake of caffeinated beverages as well as the type of their drinks, timing of initial drink, the frequency and amount of intake, and whether they changed consumption patterns since becoming pregnant. Sources of caffeine included coffee, tea, caffeinated soda and hot chocolate.

Researchers estimated the amount of caffeine intake in various types of beverages using the following conversion: For every 150 milliliters of beverage, 100 milligrams for caffeinated coffee, 2 milligrams for decaffeinated coffee, 39 milligrams for caffeinated tea, 15 milligrams for caffeinated soda, and 2 milligrams for hot chocolate. Information on other potential risk factors for miscarriage -- including maternal age, race, education, household income marital status, smoking, alcohol consumption, hot tub use, exposure to magnetic fields during pregnancy, and symptoms related to pregnancy such as nausea and vomited -- also were collected during the in-person interview and controlled during analyses. Pregnancy outcomes up to 20 weeks of gestation were determined for all participants.

Ov
'/>"/>

Contact: Danielle Cass
Danielle.X.Cass@kp.org
510-267-5354
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Kaiser Permanente Provides $1.4 Million in Holiday Gifts to 40 Metro Atlanta Nonprofits
2. Kaiser Permanente -- Group Health study shows depression worsens HIV treatment
3. GDS / Denex Dental Selected by Kaiser Permanente Northwest
4. Kaiser Permanente and Discovery Health Team Up to Fight Childhood Obesity Epidemic
5. Kaiser Permanente Opens 15th Medical Facility in Georgia
6. Kaiser Permanente/Harvard Medical School study links lack of sleep to weight gain for new moms
7. Kaiser Permanente Recognized by NCQA for Innovative Program to Reduce Health Care Disparities
8. U.S. News & World Report Names Kaiser Permanente Top-Ranked Health Plan in Georgia
9. Kaiser Foundation Health Plan Earnings Support Investments in Member and Community Health
10. Kaiser Permanente Puts Personal Health Record Front and Center
11. Following Heart Disease Guidelines Saves Lives, According to a Kaiser Permanente Abstract Presented at AHA Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3Health News:VHI Releases Annual Industry Report - Highlights Hospital, Nursing Facility Efficiency 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 3Health News:MassMutual Recognized as One of America's Healthiest Companies 2Health News:MassMutual Recognized as One of America's Healthiest Companies 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Mesa Labs Increases Quarterly Dividend 61255 1Neogen to Ring NASDAQs Closing Bell 14815 1Neogen to Ring NASDAQs Closing Bell 14815 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 1Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 3